Genetic determinants of warfarin dosing in the Han-Chinese population

Pharmacogenomics

Volumn 10, Issue 12, 2009, Pages 1905-1913

[No Author Info available]

Author keywords

CYP2C9; Han Chinese; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

ALLOPURINOL; AMIODARONE; APOLIPOPROTEIN E; ATORVASTATIN; BLOOD CLOTTING FACTOR 7; CALUMENIN; CARBAMAZEPINE; CELL PROTEIN; CYTOCHROME P450 2C18; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; EPOXIDE HYDROLASE 1; FENOFIBRATE; FLUINDOSTATIN; GAMMA GLUTAMYL CARBOXYLASE; GEMFIBROZIL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; PROTEIN C; PROTEIN ORM1; PROTEIN ORM2; PROTHROMBIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; MUTATIONAL ANALYSIS; PHARMACOGENETICS; RHEUMATIC HEART DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; TAIWAN; WARFARIN;

EID: 73649117856     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.106     Document Type: Article

References (49)

1. Hirsh J: Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. Am. Heart J. 123, 1115-1122 (1992).
2. Hirsh J, Dalen J, Anderson DR et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, S8-S21 (2001).
3. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A: Antithrombotic therapy in atrial fibrillation. Chest 108, S352-S359 (1995).
4. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 108, S371-S379 (1995).
5. Loebstein R, Yonath H, Peleg D et al.: Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70, 159-164 (2001).
6. Takahashi H, Wilkinson GR, Caraco Y et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263 (2003). One of the first papers to show population differences in VKORC1 SNPs.
7. Zhao F, Loke C, Rankin SC et al.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76, 210-219 (2004).
8. Bogousslavsky J, Regli F: Anticoagulant-induced intracerebral bleeding in brain ischemia. Evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke. Acta Neurol. Scand. 71, 464-471 (1985).
9. Gullov AL, Koefoed BG, Petersen P: Bleeding complications to long-term oral anticoagulant therapy. J. Thromb. Thrombolysis 1, 17-25 (1994).
10. Landefeld CS, Beyth RJ: Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95, 315-328 (1993).
11. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525-538 (1998).
12. Rettie AE, Korzekwa KR, Kunze KL et al.: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
13. Takahashi H, Echizen H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40, 587-603 (2001).
14. Furuya H, Fernandez-Salguero P, Gregory W et al.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392 (1995).
15. Nasu K, Kubota T, Ishizaki T: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409 (1997).
16. Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270 (2002).
17. Ngow HA, Wan Khairina WM, Teh LK et al.: CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med. J. 50, 490-493 (2009).
18. Bell RG, Matschiner JT: Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature 237, 32-33 (1972).
19. Wallin R, Martin LF: Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J. Clin. Invest. 76, 1879-1884 (1985).
20. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
21. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
22. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
23. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
24. Wen MS, Lee M, Chen JJ et al.: Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84, 83-89 (2008).
25. Wu AH, Wang P, Smith A et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9, 169-178 (2008).
26. Gage BF, Eby C, Johnson JA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
27. Cain D, Hutson SM, Wallin R: Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J. Biol. Chem. 272, 29068-29075 (1997).
28. Loebstein R, Vecsler M, Kurnik D et al.: Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77, 365-372 (2005).
29. Wajih N, Sane DC, Hutson SM, Wallin R: The inhibitory effect of calumenin on the vitamin K-dependent γ-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J. Biol. Chem. 279, 25276-25283 (2004).
30. Presnell SR, Stafford DW: The vitamin K-dependent carboxylase. Thromb. Haemost. 87, 937-946 (2002).
31. Cha PC, Mushiroda T, Takahashi A et al.: High-resolution SNP and haplotype maps of the human γ-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J. Hum. Genet. 52, 856-864 (2007).
32. Lin PJ, Jin DY, Tie JK, Presnell SR, Straight DL, Stafford DW: The putative vitamin K-dependent γ-glutamyl carboxylase internal propeptide appears to be the propeptide binding site. J. Biol. Chem. 277, 28584-28591 (2002).
33. Presnell SR, Tripathy A, Lentz BR, Jin DY, Stafford DW: A novel fluorescence assay to study propeptide interaction with γ-glutamyl carboxylase. Biochemistry 40, 11723-11733 (2001).
34. Rieder MJ, Reiner AP, Rettie AE: γ-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J. Thromb. Haemost. 5, 2227-2234 (2007).
35. Kimura R, Miyashita K, Kokubo Y et al.: Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120, 181-186 (2007).
36. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M: γ-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 106, 3673-3674 (2005).
37. Shikata E, Ieiri I, Ishiguro S et al.: Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103, 2630-2635 (2004).
38. Saupe J, Shearer MJ, Kohlmeier M: Phylloquinone transport and its influence on γ-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am. J. Clin. Nutr. 58, 204-208 (1993).
39. Berkner KL, Runge KW: The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J. Thromb. Haemost. 2, 2118-2132 (2004). Comprehensive study demonstrating the association of several genes with warfarin dose in the Caucasian population.
40. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
41. Lal S, Sandanaraj E, Jada SR et al.: Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol. 65, 260-264 (2008).
42. Otagiri M, Maruyama T, Imai T, Suenaga A, Imamura Y: A comparative study of the interaction of warfarin with human α 1-acid glycoprotein and human albumin. J. Pharm. Pharmacol. 39, 416-420 (1987).
43. Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008). Genome-wide association study showing the association of CYP4F2 with warfarin dose.
44. Takeuchi F, McGinnis R, Bourgeois S et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, E1000433 (2009).
45. Tsai MF, Lin YJ, Cheng YC et al.: PrimerZ: streamlined primer design for promoters, exons and human SNPs. Nucleic Acids Res. 35, W63-W65 (2007).
46. Loebstein R, Dvoskin I, Halkin H et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109, 2477-2480 (2007).
47. Watala C, Golanski J, Kardas P: Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients. Thromb. J. 1, 7 (2003).
48. Yoshizawa M, Hayashi H, Tashiro Y et al.: Effect of VKORC1 -1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb. Res. 124, 161-166 (2009).
49. Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).